Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1

Interventions

Injections 9Interviews as Topic 5Carboplatin 5Cisplatin 4toripalimab 3fludarabine 3Pemetrexed 3Iodine-125 3Immune Checkpoint Inhibitors 3Fluorodeoxyglucose F18 3tislelizumab 2envafolimab 2Specimen Handling 2Paclitaxel 2Oxaliplatin 2Drug Therapy 2Cyclophosphamide 2Cryosurgery 2Capecitabine 2Blood Specimen Collection 2trastuzumab deruxtecan 1spartalizumab 1somatostatin receptor 2 1sintilimab 1regorafenib 1pembrolizumab 1osimertinib 1olaparib 1nabiximols 1malic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ivarmacitinib × Other solid neoplasm × Clear all
NCT07313202 2025-12-31

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Fujian Cancer Hospital

Phase 2 Not yet recruiting
72 enrolled
Other solid neoplasm

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

Data powered by HemOnc (CC BY 4.0) Colophon âš¡